Gao Huiqiao, Lu Qi, Zhang Jianxin
Department of Obstetrics and Gynecology, Beijing Chao-Yang Hospital Affiliated to Capital Medical University, Beijing, 100020, People's Republic of China.
Int J Womens Health. 2025 Mar 14;17:751-760. doi: 10.2147/IJWH.S506565. eCollection 2025.
We sought to study the expression of FGFR2 and c-Met and evaluate the correlation between the two proteins in a series of endometrial cancer patients as well as the prognostic significance of the two markers in endometrium carcinoma.
Patients who were diagnosed with endometrial cancer and had undergone surgical treatment in Beijing Chao-Yang Hospital, Capital Medical University from November 2004 to June 2011 were included in this study. Tissue microarray construction, immunohistochemical staining and scoring were employed to study the expression of FGFR2 and c-Met. SPSS version 22.0 was used to evaluate the correlation between FGFR2 and c-Met expression and the prognosis prediction value of the two markers.
In total, 109 patients were included in this study. The median age was 56 years (ranges, 30-79). The most common histologic tumor subtype was adenocarcinoma (86.2%). The five-year survival rate was 87.2%. Significantly different FGFR2 expression was observed among patients with different disease stages (p < 0.001), depths of myometrial invasion (p = 0.001) and lymph node status (p < 0.001). C-Met expression was also increased in tissues from patients with advanced stage disease, deep myometrial invasion and lymph node metastasis (p < 0.001, p = 0.031 and p < 0.001, respectively). The expression of FGFR2 and c-Met was increased in the group with poorer prognosis (overall survival < 5 years) (p = 0.002 and p = 0.023, respectively). Moreover, a strong positive correlation was observed between FGFR2 and c-Met expression (p < 0.01, r = 0.656). FGFR2 was a significant factor that influence the FIGO stage.
Higher expression of FGFR2 and c-Met is associated with more advanced stage, deeper myometrial invasion and lymph node metastasis in endometrial cancer and poorer prognosis. In addition, high expression of FGFR2 is correlated with high c-Met expression.
我们旨在研究一系列子宫内膜癌患者中FGFR2和c-Met的表达情况，评估这两种蛋白之间的相关性，以及这两种标志物在子宫内膜癌中的预后意义。
本研究纳入了2004年11月至2011年6月期间在首都医科大学附属北京朝阳医院被诊断为子宫内膜癌并接受手术治疗的患者。采用组织芯片构建、免疫组织化学染色及评分来研究FGFR2和c-Met的表达。使用SPSS 22.0软件评估FGFR2和c-Met表达之间的相关性以及这两种标志物的预后预测价值。
本研究共纳入109例患者。中位年龄为56岁（范围30 - 79岁）。最常见的组织学肿瘤亚型为腺癌（86.2%）。五年生存率为87.2%。在不同疾病分期（p < 0.001）、肌层浸润深度（p = 0.001）和淋巴结状态（p < 0.001）的患者中观察到FGFR2表达存在显著差异。在晚期疾病、肌层浸润深和有淋巴结转移的患者组织中，c-Met表达也增加（分别为p < 0.001、p = 0.031和p < 0.001）。在预后较差（总生存期<5年）的组中，FGFR2和c-Met的表达增加（分别为p = 0.002和p = 0.023）。此外，观察到FGFR2和c-Met表达之间存在强正相关（p < 0.01，r = 0.656）。FGFR2是影响国际妇产科联盟（FIGO）分期的一个重要因素。
FGFR2和c-Met的高表达与子宫内膜癌更晚期、更深的肌层浸润、淋巴结转移及更差的预后相关。此外，FGFR2的高表达与c-Met的高表达相关。
